ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Food and Drug Administration has accepted Anixa Biosciences’s investigational new drug application, clearing the company to begin clinical trials of its chimeric antigen receptor T-cell (CAR-T) treatment for ovarian cancer. Moffitt Cancer Center developed the therapy, which consists of T cells from a person with ovarian cancer that are engineered to recognize the follicle stimulating hormone receptor. CAR-T has been successful in treating blood cancers but has been difficult to adapt to solid tumors.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X